多囊卵巢综合征患者联合促排卵治疗结局的预测

The predicition of the outcome of PCOS patients with combined ovulation induction

目的:探究预测多囊卵巢综合征患者促排卵治疗结局的因素。方法:收集2018年12月至2020年12月在本院门诊就诊的接受LE联合HMG联合促排卵治疗的118例多囊卵巢综合征(Polycystic Ovary Syndrome,PCOS)患者的临床资料,根据接受促排卵治疗后的结局将患者分为反应组和无反应组。结果:体重指数(Body Mass Index,BMI)、黄体生成素、黄体生成素/卵泡刺激素(Luteinizing Hormone/Follicle Stimulating Hormone ratio,LH/FSH)比值在两组间差异具有统计学意义(P<0.05),用于预测结局的最佳界值分别为24.29kg/m^(2),5.78mIU/mL,0.96。结论:体重指数、黄体生成素、黄体生成素/卵泡刺激素比值均可以作为来曲唑(Letrozol,LE)联合人绝经期尿促性激素(Human Menopausal Gonadotropin,HMG)促排卵治疗结局的预测指标,且联合指标预测能力明显优于单独使用各指标。

Objective:To analyze the predictive effect on the outcome of PCOS patients received combined ovulation induction(Letrozol and Human Menopausal Gonadotropin).Methods:118 young PCOS outpatients with ovulation dysfunction from December 2018 to December 2020 were included as the study members in the retrospective analysis.They were divided into Reaction Group and Non-reaction Group based on the outcome of PCOS patients with LE+HMG combined ovulation induction.Results:Between the Non-reaction Group and the Reaction Group,the difference of BMI average level,LH level and LH/FSH ratio were statistically signficant(P<0.05).And their cut-off values were 24.29kg/m^(2),5.78mIU/mL and 0.96.Conclusion:BMI,LH and LH/FSH ratio can be used as the predictors of Letrozol combined Human Menopausal Gonadotropin ovulation induction,and combined application of each index is better than using a single index.